No Picture
News

Synthetic Biologist Marc Salit Named MITRE Fellow

BEDFORD, Mass. & MCLEAN, Va.–(BUSINESS WIRE)–MITRE named Marc Salit a MITRE Fellow to lead a major expansion in MITRE’s synthetic biology work. Salit will lead the development of a new Open BioFoundry to develop fundamental tools and accelerate applied capabilities in engineering biological systems. This will include the development of… Click here to view original post… […]

No Picture
News

Applied BioMath, LLC Announces Participation at the Cytokine-Based Cancer Immunotherapies Summit

CONCORD, Mass.: CONCORD, Mass., Nov. 29, 2021 /PRNewswire/ — Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their participation at the Cytokine-Based Cancer Immunotherapies Summit occurring November 30th to December 2nd, 2021… Click here to view original post… […]

No Picture
News

Adagio stock soars on hopes that antibody will protect against omicron

Adagio Therapeutics Inc. is riding high after the company said its experimental antibody is likely to be just as effective against the omicron variant of the coronavirus as it is against previous variants. The antibody, a drug called ADG20, affords protection for up to one year, according to the firm…. Click here to view original post… […]

No Picture
News

EQRx to Present at the 4th Annual Evercore ISI HealthCONx Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced that management will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference. The fireside chat is scheduled for Thursday, December 2nd… Click here to view original post… […]

No Picture
News

Sage Therapeutics to Host Sage FutureCast Webcast

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that it will host Sage FutureCast: An R&D and Portfolio Review on Tuesday, December 14 from 8:00 a.m…. Click here to view original post… […]